7/27/2011

U.K.'s National Institute for Health and Clinical Excellence has recommended the use of Celgene's thalidomide in combination with two other treatments as first-line treatment for patients with multiple myeloma who cannot tolerate high-dose chemotherapy and stem cell transplants. NICE said patients who cannot use thalidomide can use Velcade as an alternative drug.

Full Story:
Bloomberg

Related Summaries